[1] Clump DA,Bauman JE,Ferris RL. Cancer of the oropharynx [J].Surg Oncol Clin N Am,2015,24(3):509-520.[2] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015 [J]. CA Cancer J Clin,2016,66(2):115-132.[3] Nishimura R,Tabata K,Arakawa M,et al. Isobavachalcone,a chalcone constituent of Angelica keiskei,induces apoptosis in neuroblastoma [J]. Biol Pharm Bull,2007,30(10):1878-1883.[4] Jing H,Zhou X,Dong X,et al. Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells [J]. Cancer Lett,2010,294(2):167-177.[5] Kuete V,Mbaveng AT,Zeino M,et al. Cytotoxicity of three naturally occurring flavonoid derived compounds (artocarpesin,cycloartocarpesin and isobavachalcone) towards multi-factorial drug-resistant cancer cells [J]. Phytomedicine,2015,22(12):1096-1102.[6] Funk GF,Karnell LH,Robinson RA,et al. Presentation,treatment,and outcome of oral cavity cancer a National Cancer Data Base report [J]. Head Neck,2002,24(2):165-180.[7] Akihisa T,Tokuda H,Hasegawa D,et al. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects [J]. J Nat Prod,2006,69(1):38-42.[8] Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones [J]. Eur J Med Chem,2007,42(2):125-137.[9] Szliszka E,Jaworska D,Ksek M,et al. Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells [J]. Int J Mol Sci,2012,13(11):15343-15359.[10] Szliszka E,Czuba ZP,Mazur B,et al. Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells [J]. Int J Mol Sci,2009,11(1):1-13.[11] Adams JM,Cory S. The Bcl-2 Protein family:arbiters of cell survival [J]. Science,1998,281(5381):1309-1312.[12] Zhang B,Liu M,Tang HK,et al. The expression and significance of MRP1,LRP,TOPOⅡβ,and BCL2 in tongue squamous cell carcinoma [J]. J Oral Pathol Med,2012,41(2):141-148.[13] Meterissian SH,Kontogiannea M,Po J,et al. Apoptosis induced in human colorectal carcinoma by anti-Fas antibody [J]. Ann Surg Oncol,1997,4(2):169-175.[14] Dent P. Crosstalk between ERK,AKT and cell survival [J]. Cancer Biol Ther,2014,15(3):245-246.[15] Briest F,Grabowski P.PI3K-AKT-mTOR signaling and beyond:the complex network in gastroenteropancreatic neuroendocrine neoplasms [J]. Theranostics,2014,4(4):336-365.[16] Polivka J Jr,Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway [J]. Pharmacol Ther,2014,142(2):164-175. |